These findings indicate that while the combined sorafenib and azacitidine treatment yields an overall response rate of nearly 50% in this elderly, high‐risk AML population, the FLT3‐ITD allelic burden did not significantly predict survival or response outcomes. The gene discussed is FLT3; the disease is acute myeloid leukemia.